Antibody shows encouraging results for treating high-risk follicular lymphoma and marginal zone lymphoma
Two clinical trials testing the antibody loncastuximab tesirine (Zynlonta) showed encouraging results in patients with ...
News Medical10d
Antibody trials show encouraging results in patients with high-risk forms of two blood cancers
Two clinical trials testing the antibody loncastuximab tesirine (Zynlonta) showed encouraging results in patients with high-risk forms of two blood cancers ... options also show high efficacy ...
EurekAlert!11d
ASH 2024: Antibody shows encouraging results for treating high-risk follicular lymphoma and marginal zone lymphoma
Presentation: Two clinical trials testing the antibody loncastuximab tesirine (Zynlonta) showed encouraging results in patients with high-risk forms of two blood cancers – follicular lymphoma and ...
Novel bioluminescent immunosensor shows promise for quantitative point-of-care testing
A novel nanobody-based immunosensor, designed to function stably in undiluted biological fluids and harsh conditions, has ...
Neuroscience News1d
Brain-Targeted mRNA Delivery Breaks the Blood-Brain Barrier
Researchers have developed lipid nanoparticles (LNPs) that cross the blood-brain barrier (BBB) and precisely target brain cells, a major step toward treating neurological diseases like Alzheimer’s.
Glenmark Pharma surges 4% after first clinical data of blood cancer drug shows positive signs
Positive clinical trails results strengthen the case for approval of Glenmark Pharma's blood cancer drug. If successful, it ...
Science Daily7d
Research shows new treatment could delay cancer progression in patients with high-risk smoldering multiple myeloma
A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition can progress to active multiple myeloma, a type of blood cancer. High-risk ...